查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726275

全球子宮頸癌篩檢、診斷和癌前發育不良治療市場（按類型和地區）：細分市場預測（2025-2035）

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market By Type (Cervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment), By Region, And Segment Forecasts, 2025 - 2035
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

子宮頸癌篩檢、診斷和癌前發育不良治療市場的成長和趨勢：

根據 Grand View Research, Inc. 的最新報告，全球子宮頸癌篩檢、診斷和癌前發育不良治療市場規模預計到 2035 年將達到 156.7504 億美元，2025 年至 2035 年的複合年成長率為 5.90%。

市場成長的動力來自於技術進步、意識的增強以及對預防性醫療保健的高度關注。儘管挑戰依然存在，包括醫療保健服務的不平等和子宮頸癌的持續負擔，但聯邦機構、醫療保健提供者和社區組織之間的合作努力正在幫助改善結果。持續投資於早期發現、創新治療方法和公平獲得護理對於降低子宮頸癌發病率和死亡率至關重要。隨著市場擴大，相關人員必須優先考慮具有成本效益的解決方案和能夠全面應用於不同人群的創新篩選技術。

先進篩選和處理技術的快速採用是推動市場擴張的主要因素。例如，2024 年 7 月，Aspirus Woodruff 診所將引進環形電外科切除術 (LEEP) 機器，為萊克蘭女性提供尖端子宮頸治療。這項技術是子宮頸發育不良治療的一項重大進步，委員會認證的婦科醫生 Joel Wenland 醫學博士強調了其在子宮頸癌預防中的重要作用。同樣，2021 年 1 月，Pregna International Inc. 推出了 CryoPop 冷凍治療設備，鞏固了其在女性醫療保健領域的領導地位。 CryoPop 是與 Jhpiego 合作開發的，符合世界衛生組織消除子宮頸癌的全球策略，並將增加世界各地獲得子宮頸癌前治療的機會。

子宮頸癌篩檢和治療行業最大的成長機會之一是開發和實施具有成本效益、可訪問的篩檢技術。子宮頸抹片在降低高所得國家子宮頸癌發病率方面一直發揮著重要作用，但其對專業人力資源和實驗室基礎設施的依賴限制了其在資源受限環境中的可行性。為了應對這些挑戰，世界衛生組織（WHO）更新了其指南，納入了更容易獲得的篩檢方法，旨在提高篩檢率並促進服務不足地區的早期發現。世界衛生組織《消除子宮頸癌全球策略》的目標是到2030年，透過高通量檢測對70%的35歲和45歲女性進行篩檢。這項舉措凸顯了世界衛生組織致力於擴大全球篩檢計畫的承諾，從而增加了市場的成長潛力。

傳統的子宮頸癌篩檢方法，例如子宮頸抹片，長期以來一直是黃金標準。然而，液基細胞學和高危險 HPV DNA 檢測等技術進步正日益補充它。這些方法正在提高樣本品質、增強診斷準確性、縮短週轉時間並使早期檢測更有效。

人工智慧 (AI) 在子宮頸癌診斷中的應用改變了遊戲規則，徹底提高了篩檢的效率。基於人工智慧的工具現在可以高精度地分析巴氏抹片影像，並識別可能表明癌前病變或癌性病變的異常細胞。例如，人工智慧診斷系統可以自動評估數位化細胞學玻片並標記潛在異常以進行進一步臨床測試。這不僅減少了人為錯誤，而且加快了診斷過程，從而加快了醫療干預。

人工智慧的影響不僅限於診斷，還涉及治療計劃。機器學習和預測分析可以使醫療保健提供者更好地評估疾病進展並提供個人化的治療方法。 LEEP 和冷凍療法等技術極大地受益於人工智慧的精確性，確保了微創、高效的干涉和更快的恢復時間。在醫療保健基礎設施有限的地區，人工智慧主導的解決方案可以有效地擴展篩檢項目，使高品質的診斷和治療更容易獲得。

子宮頸癌篩檢、診斷及癌前發育不良治療市場：概述

  • 按類型分類，子宮頸癌篩檢領域將在 2024 年佔據市場最大收益佔有率，達到 48.29%，預計在預測期內將以最快的複合年成長率成長。子宮頸癌篩檢對於早期發現和預防至關重要，並利用一系列設備和技術來提高準確性、可近性和患者治療效果。傳統的子宮頸抹片採集工具仍然是篩檢的支柱，尤其是在缺乏先進診斷基礎設施的地區。
  • 由於切片檢查設備和陰道鏡的進步，以及這些技術的採用和需求的增加，子宮頸癌診斷市場預計將在預測期內出現顯著的複合年成長率。 2024 年 12 月，聯邦首都特區管理局引進了陰道鏡檢查機，旨在提高女性子宮頸癌的早期發現和治療率。這項開創性的舉措有望徹底改變該地區的醫療保健服務。
  • 北美在 2024 年佔據市場主導地位，銷售額佔有率最大，為 41.17%。過去幾十年來，北美在降低子宮頸癌發病率和死亡率方面取得了顯著進展，主要是透過大規模子宮頸癌篩檢計畫。這些舉措在很大程度上依賴於子宮頸抹片抹片檢查以及最近的人類乳突病毒 (HPV) 檢測。然而，儘管許多地區的整體篩檢率很高，但在篩檢參與度和後續護理方面仍然存在差異，尤其是在服務不足的人群中。為了解決這些差異，北美各地的醫療保健系統正在採用創新的解決方案。 FDA 最近核准了HPV 自我採樣檢測，例如 cobas HPV 檢測和 BD Onclarity HPV 檢測，這為那些可能由於不適、文化敏感性或過去創傷而避免進行傳統骨盆檢查的女性提供了一個有希望的選擇。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 子宮頸癌篩檢、診斷和癌前發育不良治療市場：促進因素、趨勢和範圍

  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 市場機會分析
  • 子宮頸癌篩檢、診斷及癌前發育不良治療市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章子宮頸癌篩檢、診斷和癌前發育不良治療市場：定性資料分析

  • 子宮頸癌篩檢指南
  • 利用子宮頸癌篩檢
  • 世衛組織和其他政策委員會的立場
  • 子宮頸癌篩檢的障礙

第5章子宮頸癌篩檢、診斷和癌前發育不良治療市場：市場趨勢分析

  • 新興技術和創新趨勢
  • 兌換狀態
  • 子宮頸癌發生率和盛行率
  • 目標人口總數
  • 人類乳突病毒(HPV)疫苗接種族群趨勢評估

第6章子宮頸癌篩檢、診斷和癌前發育不良治療市場：按類型估計和趨勢分析

  • 按類型分類的市場佔有率（2024 年和 2035 年）
  • 細分儀表板
  • 子宮頸癌篩檢、診斷和癌前發育不良治療市場：按類型展望
  • 子宮頸癌篩檢
    • 子宮頸抹片採集設備
    • HPV檢測平台
    • 視線刷
    • 自取套件
    • 其他
  • 子宮頸癌診斷
    • 窺器
    • 子宮頸切片檢查裝置
    • 人工智慧影像陰道鏡檢查（數位）
    • 其他
  • 癌前病變治療
    • LEEP（環狀電外科切除術）裝置
    • 冷凍療法
    • 熱燒蝕
    • 其他

第7章子宮頸癌篩檢、診斷和癌前發育不良治療市場：區域估計和趨勢分析（按產品、類型和最終用途）

  • 按地區分類的市場佔有率分析（2024 年和 2035 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2035）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 主要企業市場佔有率/地位分析（2024年）
  • 公司簡介
    • F. Hoffmann-La Roche
    • BD
    • Abbott
    • QIAGEN
    • Hologic, Inc.
    • CooperSurgical Inc.
    • MedGyn Products, Inc
    • WISAP Medical Technology GmbH
    • Liger Medical
    • Utah Medical Products, Inc.
Product Code: GVR-4-68040-554-5

Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Growth & Trends:

The global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size is anticipated to reach USD 15,675.04 million by 2035 and is projected to grow at a CAGR of 5.90% from 2025 to 2035, according to a new report by Grand View Research, Inc. The market growth is driven by technological advancements, increased awareness, and a strong focus on preventive care. Despite persistent challenges such as disparities in healthcare access and the ongoing burden of cervical cancer, collaborative efforts among federal agencies, healthcare providers, and community organizations are fostering improved outcomes. Continued investment in early detection, innovative treatment options, and equitable healthcare access will be critical in reducing cervical cancer incidence and mortality. As the market expands, stakeholders must prioritize cost-effective solutions and innovative screening technologies to ensure comprehensive coverage across diverse populations.

The rapid adoption of advanced screening and treatment technologies has been a key driver of market expansion. For instance, in July 2024, women in Lakeland gained access to state-of-the-art cervical care at Aspirus Woodruff Clinic with the introduction of a Loop Electrosurgical Excision Procedure (LEEP) machine. This technology marks a major step forward in the treatment of cervical dysplasia, with Dr. Joelle Wennlund, a Board-certified Gynecologist, emphasizing its critical role in cervical cancer prevention. Similarly, in January 2021, Pregna International Ltd. reinforced its position as a leader in women's healthcare by launching the CryoPop cryotherapy device. Developed in partnership with Jhpiego, CryoPop enhances accessibility to cervical pre-cancerous lesion treatment worldwide, aligning with WHO's global strategy for cervical cancer elimination.

One of the most significant growth opportunities in the cervical cancer screening and treatment industry is the development and implementation of cost-effective, accessible screening technologies. While Pap smears have historically played a crucial role in reducing cervical cancer rates in high-income countries, their reliance on specialized personnel and laboratory infrastructure limits their feasibility in resource-constrained settings. To address these challenges, the World Health Organization (WHO) has updated its guidelines to include more accessible screening methods, aiming to increase coverage and promote early detection in underserved regions. WHO's Global Strategy for the Elimination of Cervical Cancer seeks to screen 70% of women with a high-performance test at ages 35 and 45 by 2030. This initiative highlights the organization's commitment to expanding global screening programs, reinforcing the market's growth potential.

Traditional cervical cancer screening methods, such as Pap smears, have long been the gold standard. However, they are increasingly being supplemented by technological advancements such as liquid-based cytology and high-risk HPV DNA testing. These approaches improve sample quality, enhance diagnostic accuracy, and reduce turnaround time, making early detection more effective.

The integration of artificial intelligence (AI) in cervical cancer diagnostics has been a game changer, revolutionizing screening efficiency. AI-driven tools can now analyze cytological images with high precision, identifying abnormal cells that could indicate pre-cancerous or cancerous lesions. For example, AI-powered diagnostic systems can automatically evaluate digitized cytology slides, flagging potential abnormalities for further clinical review. This not only reduces human error but also expedites diagnostic processes, leading to faster medical interventions.

AI's impact extends beyond diagnostics to treatment planning. With machine learning and predictive analytics, healthcare providers can better assess lesion progression and offer personalized treatment approaches. Technologies such as LEEP and cryotherapy benefit significantly from AI precision, ensuring minimally invasive, highly effective interventions with shorter recovery times. In regions where healthcare infrastructure is limited, AI-driven solutions help scale screening programs efficiently, making high-quality diagnostics and treatment more accessible.

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Report Highlights:

  • Based on type, the cervical cancer screening segment led the market with the largest revenue share of 48.29% in 2024 and is expected to grow at the fastest CAGR during the forecast period. Cervical cancer screening is essential for early detection and prevention, utilizing a variety of devices and technologies to enhance accuracy, accessibility, and patient outcomes. Traditional Pap smear collection tools remain a cornerstone of screening, particularly in areas lacking advanced diagnostic infrastructure
  • The cervical cancer diagnostics market is anticipated to witness at a substantial CAGR during the forecast period, driven by advancements in biopsy devices and colposcopes, alongside increasing adoption and demand for these technologies. In December 2024, the Federal Capital Territory Administration introduced a colposcopy machine designed to enhance early detection and treatment of cervical cancer among women. This groundbreaking initiative is expected to revolutionize healthcare delivery in the region.
  • North America dominated the market with the largest revenue share of 41.17% in 2024. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs. These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations. To address these gaps, healthcare systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women who may avoid traditional pelvic exams due to discomfort, cultural sensitivities, or past trauma

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape

Chapter 4. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market, Qualitative Data Analysis

  • 4.1. Screening Guidelines for Cervical Cancer
  • 4.2. Utilization of Cervical Cancer Screening
  • 4.3. WHO and Other Policy Board Positions
  • 4.4. Barriers to Cervical Cancer Screening

Chapter 5. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market, Market Developments Analysis

  • 5.1. Emerging Technology and Innovation Trends
  • 5.2. Reimbursement Landscape
  • 5.3. Incidence and Prevalence of Cervical Cancer
  • 5.4. Total Eligible Population
  • 5.5. Assessing Trends in HPV-Vaccinated Populations

Chapter 6. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market: Type Estimates & Trend Analysis

  • 6.1. Type Market Share, 2024 & 2035
  • 6.2. Segment Dashboard
  • 6.3. Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market by Type Outlook
  • 6.4. Cervical Cancer Screening
    • 6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.4.2. Pap Smear Collection Devices
      • 6.4.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.4.3. HPV Testing Platforms
      • 6.4.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.4.4. Cytobrush
      • 6.4.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.4.5. Self-collection kits
      • 6.4.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5. Cervical Cancer Diagnostics
    • 6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.5.2. Colposcopes
      • 6.5.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.5.3. Cervical Biopsy Devices
      • 6.5.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.5.4. Colposcopes with AI Imaging (Digital)
      • 6.5.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.5.5. Others
      • 6.5.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6. Pre-cancerous Lesion Treatment
    • 6.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
      • 6.6.1.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.6.2. LEEP (loop electrosurgical excision procedure) Machine
      • 6.6.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.6.3. Cryotherapy
      • 6.6.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.6.4. Thermal Ablation
      • 6.6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.6.5. Others
      • 6.6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)

Chapter 7. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

  • 7.1. Regional Market Share Analysis, 2024 & 2035
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2035:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2035 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2035 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share/position analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Technology Type benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. BD
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Technology Type benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Abbott
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Technology Type benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. QIAGEN
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Technology Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Hologic, Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Technology Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. CooperSurgical Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Technology Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. MedGyn Products, Inc
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Technology Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. WISAP Medical Technology GmbH
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Technology Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Liger Medical
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Technology Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Utah Medical Products, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Technology Type benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 4 US Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 5 Canada Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 6 Mexico Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 7 Europe Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 8 UK Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 9 Germany Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 10 France Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 11 Italy Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 12 Spain Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 13 Denmark Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 14 Sweden Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 15 Norway Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 16 Asia Pacific Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 17 Japan Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 18 China Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 19 India Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 20 Australia Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 21 South Korea Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 22 Thailand Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 23 Latin America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 24 Brazil Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 25 Argentina Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 26 MEA Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 27 South Africa Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 28 Saudi Arabia Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 29 UAE Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
  • Table 30 Kuwait Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market outlook
  • Fig. 9 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market driver impact
  • Fig. 15 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market restraint impact
  • Fig. 16 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market strategic initiatives analysis
  • Fig. 17 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Type analysis
  • Fig. 18 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Type outlook and key takeaways
  • Fig. 19 Cervical cancer screening market estimates and forecast, 2018 - 2035
  • Fig. 20 Pap Smear Collection Devices market estimates and forecast, 2018 - 2035
  • Fig. 21 HPV Testing Platforms market estimates and forecast, 2018 - 2035
  • Fig. 22 Cytobrush market estimates and forecast, 2018 - 2035
  • Fig. 23 Self-collection kits market estimates and forecast, 2018 - 2035
  • Fig. 24 Others market estimates and forecast, 2018 - 2035
  • Fig. 25 Cervical cancer diagnostics market estimates and forecast, 2018 - 2035
  • Fig. 26 Colposcopes market estimates and forecast, 2018 - 2035
  • Fig. 27 Cervical biopsy devices market estimates and forecast, 2018 - 2035
  • Fig. 28 Colposcopes with AI imaging (Digital) market estimates and forecast, 2018 - 2035
  • Fig. 29 Others market estimates and forecast, 2018 - 2035
  • Fig. 30 Pre-cancerous lesion treatment market estimates and forecast, 2018 - 2035
  • Fig. 31 LEEP (loop electrosurgical excision procedure) machine market estimates and forecast, 2018 - 2035
  • Fig. 32 Cryotherapy market estimates and forecast, 2018 - 2035
  • Fig. 33 Thermal ablation market estimates and forecast, 2018 - 2035
  • Fig. 34 Others market estimates and forecast, 2018 - 2035
  • Fig. 35 Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Regional movement analysis
  • Fig. 36 Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Regional outlook and key takeaways
  • Fig. 37 Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market share and leading players
  • Fig. 38 North America: SWOT
  • Fig. 39 Europe SWOT
  • Fig. 40 Asia Pacific SWOT
  • Fig. 41 Latin America SWOT
  • Fig. 42 MEA SWOT
  • Fig. 43 North America market estimates and forecasts, 2018 - 2035
  • Fig. 44 US market estimates and forecasts, 2018 - 2035
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2035
  • Fig. 46 Mexico market estimates and forecasts, 2018 - 2035
  • Fig. 47 Europe market estimates and forecasts, 2018 - 2035
  • Fig. 48 UK market estimates and forecasts, 2018 - 2035
  • Fig. 49 Germany market estimates and forecasts, 2018 - 2035
  • Fig. 50 France market estimates and forecasts, 2018 - 2035
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2035
  • Fig. 52 Spain market estimates and forecasts, 2018 - 2035
  • Fig. 53 Denmark market estimates and forecasts, 2018 - 2035
  • Fig. 54 Sweden market estimates and forecasts, 2018 - 2035
  • Fig. 55 Norway market estimates and forecasts, 2018 - 2035
  • Fig. 56 Asia Pacific market estimates and forecasts, 2018 - 2035
  • Fig. 57 China market estimates and forecasts, 2018 - 2035
  • Fig. 58 Japan market estimates and forecasts, 2018 - 2035
  • Fig. 59 India market estimates and forecasts, 2018 - 2035
  • Fig. 60 Thailand market estimates and forecasts, 2018 - 2035
  • Fig. 61 South Korea market estimates and forecasts, 2018 - 2035
  • Fig. 62 Australia market estimates and forecasts, 2018 - 2035
  • Fig. 63 Latin America market estimates and forecasts, 2018 - 2035
  • Fig. 64 Brazil market estimates and forecasts, 2018 - 2035
  • Fig. 65 Argentina market estimates and forecasts, 2018 - 2035
  • Fig. 66 Middle East and Africa market estimates and forecasts, 2018 - 2035
  • Fig. 67 South Africa market estimates and forecasts, 2018 - 2035
  • Fig. 68 Saudi Arabia market estimates and forecasts, 2018 - 2035
  • Fig. 69 UAE market estimates and forecasts, 2018 - 2035
  • Fig. 70 Kuwait market estimates and forecasts, 2018 - 2035
  • Fig. 71 Market share of key market players- Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market
  • Fig. 72 Key Company Categorization
  • Fig. 73 Company Market Share/Position Analysis, 2024
  • Fig. 74 Strategic Framework